Search Prime Grants

R01CA259370

Project Grant

Overview

Grant Description
Circadian Clock and MYC-Dependent Regulation of Cellular Transformation - Project Summary/Abstract

Colorectal cancer (CRC) is the third most diagnosed cancer in the United States. Though CRC cases in adults (55 and older) have decreased, the incidence of CRC in young adults, ages 15-40, is on an alarming rise. It is estimated that by the year 2030, a staggering 11-12% increase in early-onset (EO) cancers will be observed.

Adult cases of CRC typically harbor driver mutations in APC, a tumor suppressor that regulates WNT signaling, in addition to second hits in KRAS, BRAF, P53, and SMAD4. APC mutations are also found in early-onset CRC (EO-CRC), but a decrease in the typical second-hit driver pathways has been reported. Therefore, there is an urgent need to better define the root cause of EO-CRC.

Moreover, clinical evidence suggests that diet is likely a root underlying cause of the increased incidence in sporadic cases of EO-CRC. Interestingly, dietary challenge and timing of food intake directly impinge on the circadian clock, which is our internal pacemaker that governs sleep/wake cycles, feeding, hormonal, and other cyclic rhythms. This suggests that disruption of the circadian clock could be a major risk factor for EO cancers.

In further support of this idea, clinical data indicates that clock genes are broadly downregulated in human colorectal tumors, suggesting that suppression of the clock could be important for transformation in the intestinal epithelium. To directly address the potential links between the clock and CRC, we have developed a novel genetic mouse model to define how disruption of the circadian clock drives CRC pathogenesis.

Our preliminary data demonstrates that disruption of the clock in the intestinal epithelium drives a statistically significant increase in polyp formation. Using our mouse model system, organoid cultures reveal that clock disruption accelerates transformation in the intestinal epithelium. Based on these findings, we hypothesize that clock disruption impinges on intestinal transformation and rewires cellular metabolism to sustain the heightened demand of hyperproliferative cells.

Aim 1 will define how the clock machinery regulates genome instability and transformation in the intestine. Aim 2 will determine the role of the circadian clock in governing metabolism of intestinal epithelial cells in both mouse and human organoid systems, established from EO-CRC patient samples. Aim 3 will delineate how dietary paradigms that disrupt the circadian clock accelerate intestinal transformation.

The broader impact of our findings will outline new prevention strategies for eradicating EO-CRC and other cancers that potentially relate to disruption of the circadian clock. Additionally, our long-term goal is to achieve targeted pharmacological approaches to regulate the circadian clock and therefore minimize behavioral and lifestyle factors that potentially impinge on tumorigenesis.
Funding Goals
TO PROVIDE FUNDAMENTAL INFORMATION ON THE CAUSE AND NATURE OF CANCER IN PEOPLE, WITH THE EXPECTATION THAT THIS WILL RESULT IN BETTER METHODS OF PREVENTION, DETECTION AND DIAGNOSIS, AND TREATMENT OF NEOPLASTIC DISEASES. CANCER BIOLOGY RESEARCH INCLUDES THE FOLLOWING RESEARCH PROGRAMS: CANCER CELL BIOLOGY; CANCER IMMUNOLOGY, HEMATOLOGY AND ETIOLOGY; DNA AND CHROMOSOMAL ABERRATIONS; TUMOR BIOLOGY AND METASTASIS; AND STRUCTURAL BIOLOGY AND MOLECULAR APPLICATIONS.
Grant Program (CFDA)
Place of Performance
Irvine, California 926970001 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 419% from $587,441 to $3,046,083.
Irvine University Of California was awarded Circadian Clock & MYC in EO-CRC Pathogenesis Project Grant R01CA259370 worth $3,046,083 from National Cancer Institute in January 2021 with work to be completed primarily in Irvine California United States. The grant has a duration of 5 years and was awarded through assistance program 93.396 Cancer Biology Research. The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).

Status
(Ongoing)

Last Modified 4/20/26

Period of Performance
1/1/22
Start Date
12/31/26
End Date
89.0% Complete

Funding Split
$3.0M
Federal Obligation
$0.0
Non-Federal Obligation
$3.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01CA259370

Transaction History

Modifications to R01CA259370

Additional Detail

Award ID FAIN
R01CA259370
SAI Number
R01CA259370-2514802847
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
MJC5FCYQTPE6
Awardee CAGE
0VWL0
Performance District
CA-47
Senators
Dianne Feinstein
Alejandro Padilla

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Grants, subsidies, and contributions (41.0) $1,310,164 100%
Modified: 4/20/26